To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Företag i Kanada får börja tillverka kokain

Ett företag i den kanadensiska provinsen British Columbia har fått tillstånd att tillverka och sälja kokain på licens.

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Samuel Lagercrantz: “Companies that do this successfully will take the lead”

The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

Studie: Eli Lillys Mounjaro överglänser Novo Nordisks Wegovy

På fem olika mål för viktminskning, inklusive minskning av midjeomfång, är Eli Lillys Mounjaro överlägsen Novo Nordisks Wegovy, enligt resultatet från en första...

Neanderthal genes and Nobel Prize in a popular lecture at Bioscience

An inherited gene variant from our ”evolutionary cousins” – the extinct Neanderthals – may affect how our bodies break down certain drugs. “It’s only a matter o...

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive ...

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Wusson Accelerator AB

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

Ny tillverkare! Papenmeier för att effektivt belysa och övervaka slutna behållare

OEM Automatic välkomnar stolt Papenmeier, den tyska tillverkaren som banar väg för framstående produkter inom processbelysning och processövervakning. På OEM Au...

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Collaboration in laboratory automation

The Dutch company Synchron Lab Automation developed an automated DNA extraction system with high throughput, working very closely together with Festo. As a resu...

Bananflugor äter för njutningens skull

Har du också irriterat dig på de små ljusbruna flugorna i köket? Nu är det klarlagt – de roar sig och har kul där i fruktskålen.

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

Optimism på Xspray efter uppgörelse i patenttvist

En uppgörelse uppges ha nåtts i patenttvisten mellan svenska forskningsbolaget Xspray Pharma och läkemedelsjätten Bristol Myers Squibb (BMS) om cancerkandidaten Dasynoc.

The art of building a biologic drug

The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “W...

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.